Mologen AG is a Germany based biotechnology company. It is principally engaged in the research, development, and marketing of products in the area of molecular medicine. The company's primary focus is on oncology and severe infectious diseases. The focus of the research is the dSLIM technologies, which facilitate the use of DNA as a drug for diseases that were previously untreatable. The product pipeline of the organization includes Lefitolimod and EnanDIM.